YOKNEAM, ISRAEL--(Marketwire - Nov 2, 2011) - Syneron Medical Ltd. (NASDAQ: [ ELOS ]), the leading global aesthetic device company, announced today that Asaf Alperovitz, Chief Financial Officer, is scheduled to participate in two upcoming investor conferences, and that Louis P. Scafuri, Chief Executive Officer, is scheduled to participate in one upcoming investor conference.

The first conference is the Brean Murray, Carret & Co. Life Sciences Summit in New York City. This conference will allow institutional investors to meet with Syneron but does not include a formal presentation.

Conference: Brean Murray, Carret & Co. Life Sciences Summit
Date: Monday, November 14, 2011
Syneron Participant: Asaf Alperovitz, Chief Financial Officer

The second conference is the Lazard Capital Markets 8th Annual Healthcare Conference in New York City.

Conference: Lazard Capital Markets 8th Annual Healthcare Conference
Date and Time: 2:30 pm ET on Wednesday, November 16, 2011
Syneron Participant: Asaf Alperovitz, Chief Financial Officer

The presentation at the Lazard Conference will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at [ www.syneron.com ]. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation.

The third conference is the Leerink Swann Healthcare Management Access Day in Boston, MA. This conference will allow institutional investors to meet with Syneron but does not include a formal presentation.

Conference: Leerink Swann Healthcare Management Access Day
Date: Monday, November 21, 2011
Syneron Participant: Louis P. Scafuri, Chief Executive Officer

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: [ ELOS ]) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.